All Oncology articles
-
NewsNew bispecific T cell engager platform targets ovarian cancer in preclinical studies
Scientists at The Wistar Institute have engineered a DNA-delivered bispecific T cell engager using a ‘knob-into-hole’ antibody platform, demonstrating improved persistence and dual-antigen targeting in preclinical ovarian cancer models.
-
NewsTumour organoids may expand access to targeted cancer drugs
Two studies from Weill Cornell Medicine demonstrate that patient-derived tumour organoids can accurately replicate cancers long-term and incorporate immune microenvironments, offering new potential for personalised treatment selection.
-
NewsSpatial map reveals hidden complexity of bladder cancer tumours
Researchers at MD Anderson Cancer Center have used spatial transcriptomics to chart the internal architecture of muscle-invasive bladder cancer, revealing that luminal and basal cancer cell programmes coexist within single tumours – a finding with significant implications for treatment stratification.
-
NewsCrown Bioscience joins C-Path coalition advancing regulatory NAMs acceptance
Crown Bioscience has joined the Critical Path Institute’s New Approach Methodologies Developer Coalition, bringing patient-derived model expertise and biomarker capabilities to efforts aimed at establishing regulatory qualification frameworks for human-relevant research tools.
-
NewsNTX-301 targets treatment-resistant AML via Hippo pathway in preclinical study
A novel epigenetic therapy has demonstrated activity against treatment-resistant acute myeloid leukaemia in preclinical models, including high-risk TP53-mutant disease, by selectively reactivating the Hippo tumour-suppressor pathway.
-
NewsNew BET therapies could help beat resistance in solid cancers
A new review finds that next-generation BET-targeted therapies, including selective inhibitors and PROTACs, are addressing the clinical shortcomings of earlier compounds and reviving interest in this approach for solid tumour treatment.
-
NewsAUTAC strategy targets MCL1 to overcome myeloma treatment resistance
Scientists at VCU Massey Comprehensive Cancer Center have developed an autophagy-targeting chimera that redirects cancer cells’ own recycling machinery to degrade the survival protein MCL1, offering a potential new strategy to overcome treatment resistance in multiple myeloma.
-
NewsNew BET inhibitors could overcome barriers in solid tumour treatment
A new review examines how advances in drug design, PROTAC degraders and combination therapies are reviving the clinical prospects of BET inhibition in solid tumours, after early-generation compounds were hampered by toxicity, resistance and modest efficacy.
-
ArticleSynthetic iMSCs: reprogramming ovarian cancer from the inside out
Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic iMSCs could reprogramme the tumour microenvironment and restore anti-tumour immunity.
-
NewsATRX mutations reprogram chromatin to drive glioma progression
Scientists at MD Anderson Cancer Center have revealed how ATRX mutations restructure chromatin and activate oncogenic developmental pathways in glioma, pointing towards novel therapeutic targets including the HOXA signalling axis.
-
NewsMETTL3 protein finds new mechanism driving breast cancer metastasis
Scientists at Umeå University have uncovered a previously unknown function for the RNA-modifying protein METTL3, revealing it plays a distinct role in enabling breast cancer cells to invade surrounding tissue and form metastases – findings that could open new avenues for therapeutic targeting.
-
NewsHidden vulnerability in persister cells could prevent KRAS cancer relapse
Scientists at Chiba University have identified a metabolic vulnerability in drug-tolerant cancer cells that survive KRAS-targeted therapy, opening a potential route to combination treatments designed to prevent disease recurrence in lung, pancreatic and colorectal cancers.
-
NewsResearchers reveal how entinostat disrupts pancreatic cancer repair
Scientists at the Salk Institute have discovered how the investigational HDAC inhibitor entinostat disrupts DNA repair mechanisms in pancreatic cancer cells, potentially enabling more effective combination therapies with reduced toxicity through novel nanoparticle delivery systems.
-
NewsmRNA vaccine shows promise against childhood neuroblastoma cancer
Preclinical study demonstrates effectiveness of experimental mRNA vaccine against neuroblastoma, reducing tumour size by 70 percent and delaying development. RCSI researchers used peptide nanoparticles targeting GPC2 protein to direct immune response against cancer cells, offering potential new treatment approach for aggressive childhood malignancy.
-
NewsBlocking cathepsin B protein enhances CAR T-cell therapy effectiveness
University of Maryland researchers have discovered that blocking cathepsin B protein prevents CAR T-cells from losing effectiveness, potentially improving long-term outcomes for blood cancer patients. The preclinical findings reveal that engineered immune cells inadvertently weaken themselves by acquiring tumour fragments, a process that can be prevented through targeted protein inhibition.
-
NewsLabGenius and LG Chem partner on AI-driven cancer antibodies
LabGenius Therapeutics has partnered with LG Chem to develop next-generation multispecific antibodies targeting solid tumours. The collaboration combines AI-driven drug discovery with oncology development expertise to identify therapeutics with improved selectivity and reduced toxicity.
-
NewsNew framework standardises glioma organoid research for translational studies
A collaborative review published in Neuro-Oncology establishes a unified classification system for glioma organoid models, addressing inconsistent terminology and methodology across the rapidly expanding field.
-
ReportContext is everything: how spatial biology is changing our understanding of disease
Discover how spatial biology is revealing disease mechanisms with implications for biomarkers, immunotherapy and drug development.
-
ArticleFlow-based human tumour models reveal immune responses missed by static culture
Static cultures can miss critical immune–tumour interactions. Learn how the Mera™ flow-based human tissue model better captures T-cell activity to strengthen preclinical immunotherapy research.
-
NewsCytokine-armoured CAR T cells target glioblastoma while reducing treatment toxicity
UCLA Health researchers have developed cytokine-armoured CAR T cells that directly attack glioblastoma tumours whilst recruiting the body’s wider immune system. The engineered cells showed improved tumour control in mouse models and could address antigen heterogeneity challenges that have limited CAR T therapy success in solid tumours.